WLY · John Wiley & Sons, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adj. EBITDA margin non-GAAP | 26.2% | Fiscal 2026 | — |
| Adj. EPS non-GAAP | $4.19 | Fiscal 2026 | — |
| Adj. Operating Margin non-GAAP | 17.7% | Fiscal 2026 | — |
| Adj. Revenue non-GAAP | $1.68B | Fiscal 2026 | — |
| Adjusted EBITDA non-GAAP | $440M | Fiscal year 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 26.2% | Fiscal year 2026 | — |
|
|
|||
| Adjusted Operating Margin non-GAAP | 25.3% | Q4 2026 | — |
| AI revenue | $49M | Fiscal year 2026 | — |
| AI Subscription Customers | 19 | FY26 | — |
| COA revenue | $11M | FY26 | — |
| Corporate Expenses | $143M | FY26 | — |
| Free Cash Flow non-GAAP | $195M | Fiscal year 2026 | — |
| Free Cash Flow/ Adjusted EBITDA non-GAAP | 44% | Fiscal 2026 | — |
| Learning Adjusted EBITDA non-GAAP | $208M | Fiscal year 2026 | — |
|
|
|||
| Learning Adjusted EBITDA margin non-GAAP | 38% | Fiscal year 2026 | — |
|
|
|||
| Lifetime AI Revenue | $110M | FY26 | — |
| Nexus AI Licensing Publisher Partners | 41 | FY26 | — |
| Research Adjusted EBITDA non-GAAP | $375M | Fiscal year 2026 | — |
|
|
|||
| Research Adjusted EBITDA margin non-GAAP | 33.2% | Fiscal year 2026 | — |
|
|
|||
| Returned to shareholders | $174M | Fiscal 2026 | — |
| Top 10 Pharma Companies Served | 7 | FY26 | — |
| Net Cash Provided by Operating Activities | $103M | Q3 FY2026 year-to-date | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Publishing — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WLY
this stock
John Wiley & Sons, Inc.
|
$2.64B | +69.7% | +4.5% | 12.5 | 8.2% |
|
NYT
New York Times Co
|
$10.64B | -5.0% | -1.6% | 27.5 | 8.4% |
|
PSO
Pearson PLC
|
$9.65B | +14.4% | — | — | 0.4% |
|
SPGNY
Springer Nature AG & Co. KGaA/ADR
|
$2.32B | — | — | — | 0.0% |
|
TDAY
USA TODAY Co., Inc.
|
$965.33M | +30.7% | +13.7% | — | 13.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WLY | +4.1% | +5.1% | +70.0% | -0.4% | +69.7% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +4.5% | +2.2% | +58.4% | -3.4% | +56.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.